Board & Management

Mr. Angus St John

Chairman, Director Investment

Angus-St-John.jpg

Mr St John is Managing Director and Head of Investor Client Management for Commonwealth Bank of Australia, where he oversees global relationships with the world’s largest financial institutions. He helps these groups access investment opportunities in Australia and provides Australian companies access to global capital. He worked for leading global investment banks and management consulting firms in Australia, Singapore and the US for 20 years. He worked with several successful businesses at start-up and scale-up phase, including in healthcare, to develop business strategy, improve operating models, and achieve beneficial capital raising outcomes.

Dr. Tara Karnezis

CEO, Managing Director

Dr Karnezis has over 15 years' experience in research leadership, heading scientific programs with commercial application at Stanford University and Peter Mac. She is an expert in vascular biology with an internationally significant track record including publications in Nature, Cancer Cell and Nature Neuroscience. Dr Karnezis authored the seminal Nature paper that described Sox18 as the master-regulator of lymphatic vessel development. In addition to experience with target identification and validation, she has been involved in identifying druggable targets related to the interaction of vascular biology and oncology.

Dr. Ramin Shayan

COO, Director Clinical

Dr Shayan is a senior academic plastic surgeon with world-leading experience in both clinical and research aspects of angiosarcoma, Kaposi’s sarcoma, vascular malformations and solid malignancies that rely on their neo-angiogenesis for their blood supply. Dr Shayan is Director of the O’Brien Institute Department, St Vincent’s Institute for Medical Research. He has been active in supporting and managing ongoing research into vascular biology and its application to addressing serious clinical unmet needs.

Mr. Vince Rizzo

CFO, Director Finance

Mr Rizzo is a leading management accounting, investment and commercialization expert with experience in corporate and tax structure and R&D administration. Mr Rizzo, a director of over 25 companies, is in charge of investor relations for a private funds management company with $45 million under management. He has provided financial and investment stewardship through creation of fundraising vehicles and organization of investment rounds. In 1996 he oversaw ASX listing and exit of SDS Ltd through sale to Sandvic (AUD$110 million), then remained a director and Chairman of the Audit Committee. Mr Rizzo brings board reporting compliance. management capacity, and rigorous governance skills.

Mr. Wallace Cameron

Non-executive Director

With legal, accounting and MBA qualifications, Mr Cameron has high-level international taxation and commercial law experience in the UK, Hong Kong and Europe with Denton Hall Burgin (now Dentons). He has had significant business, board and commercialization experience as Chairman, CEO and managing director of Gribbles Pathology which became Australasia’s largest pathology services provider and a global pathology, diagnostic and analytical services and molecular science company. Mr Cameron guided Gribbles through successful exit with Healthscope in 2004. Since this sale, he has invested in Biotechnology ventures in Australia and globally.